Sector News

Novartis banks EC approval for Enerzair Breezhaler

July 7, 2020
Life sciences

The European Commission (EC) has approved Novartis’ Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma.

More specifically, the drug has been cleared as a maintenance treatment of asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and a high-dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.

Once-daily Enerzair Breezhaler is the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination available in the EU for these patients, Novartis noted.

It also includes an optional digital companion with sensor and app that confirms inhalation of the medicine, medication reminders and access to ‘objective data’ to better support therapeutic decisions.

“Novartis is working to reimagine medicine for people with uncontrolled asthma, who find it a challenge to achieve effective symptom and exacerbation control,” said Rod Wooten, head of Global Marketing, Novartis Pharmaceuticals.

“The approval of Enerzair Breezhaler with sensor and app in the EU is an example of our commitment to utilise data and digital offerings to make asthma control an achievable goal for patients and physicians.”

“Today, over 45% of asthma patients at GINA Steps 4 and 5 remain uncontrolled, demonstrating the need for new treatments, delivery approaches and patient support to ensure that medication is taken correctly and treatment goals are reached,” added Professor David Price, chair of Primary Care Respiratory Medicine, University of Aberdeen.

“Once-daily Enerzair Breezhaler plus a digital companion could help to facilitate greater collaborative disease management between physicians and patients in the EU whose asthma remains uncontrolled, despite LABA/ICS treatment.”

The approval rides on the back for data from over 3,000 asthma patients in the Phase III IRIDIUM study, in which once-daily Enerzair Breezhaler was shown to be superior to once-daily Atectura Breezhaler in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment.

Enerzair Breezhaler utilises Vectura’s formulation IP. As such, European regulatory approval of the product has triggered a $5.0 million milestone to Vectura from Novartis, following on from $1.25 million from its Japanese approval late last month.

By: Selina McKee

Source: Pharma Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach